LOKELMA (sodium zirconium cyclosilicate oral suspension) PATIENT ASSISTANCE PROGRAM
Don’t let the high cost of brand potassium binder disrupt your hyperkalemia management. We help eligible patients access Lokelma (sodium zirconium cyclosilicate oral suspension) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Lokelma (sodium zirconium cyclosilicate) is FDA-approved for the treatment of hyperkalemia in adults. Non-absorbed potassium-binding zirconium silicate that selectively binds potassium in the GI tract, increasing fecal potassium excretion. Onset within 1 hour for acute use and ongoing chronic management.
- Without assistance, brand Lokelma costs commonly run approximately $700–$1,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Lokelma for a flat $69.95 per month.
- Other potassium binders: patiromer (Veltassa — daily powder, similar mechanism, often comparable cost). Older but still used: sodium polystyrene sulfonate (Kayexalate generic — much cheaper, but slower onset, GI side effects, rare colonic necrosis especially with concurrent sorbitol). Calcium polystyrene sulfonate (Kionex generic). Acute severe hyperkalemia treatment: IV calcium gluconate (membrane stabilization), insulin + glucose (shift intracellularly), beta-2 agonists (albuterol), sodium bicarbonate (if acidemic), dialysis. Address underlying cause: discontinue or reduce K-sparing diuretics, ACE inhibitors, ARBs, MRAs, and NSAIDs where appropriate; treat acute kidney injury; adjust diet. Potassium binders enable continued use of guideline-directed therapies (ACE/ARB, MRA, finerenone, SGLT2) that would otherwise need to be discontinued for hyperkalemia.
What is Lokelma Prescription Assistance Program?
The Lokelma Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Lokelma (used for treatment of hyperkalemia) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, nephrology or cardiology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing chronic kidney disease or heart failure complicated by elevated potassium.
At AffordMyPrescriptions, our Patient Advocates handle the entire Lokelma PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your prescriber for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Lokelma hyperkalemia therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Lokelma enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your hyperkalemia treatment.
Pharmacy Price Comparison
- Without assistance, Lokelma costs hundreds of dollars per month at retail pharmacies. Discount cards and pharmacy coupons offer some relief, but they don't come close to what a Patient Assistance Program provides if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Lokelma advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$960/mo | Save substantially |
| CVS Pharmacy | ~$1,000/mo | Save substantially |
| Walmart | ~$760/mo | Save substantially |
| Costco | ~$720/mo | Save substantially |
| Patiromer (Veltassa — alt binder) | ~$900/mo | Alt newer binder |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Lokelma — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Lupron Prescription Program ?
The Lokelma Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Newer binders (Lokelma, Veltassa) have better tolerability than older generic SPS (Kayexalate), enabling chronic use that supports continued guideline-directed therapy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Lokelma:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
Coupon cards expire and require constant renewal
Still $700–$1,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Lokelma assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Lokelma Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Lokelma:
Lokelma is a non-absorbed inorganic cation exchanger that selectively traps potassium ions in the GI tract — increasing fecal potassium excretion and lowering serum potassium. Onset within 1 hour, supporting both acute hyperkalemia management and chronic suppression. Its selectivity and tolerability enable continued use of guideline-directed therapies (ACE inhibitors, ARBs, MRAs, finerenone, SGLT2 inhibitors) in CKD and HF patients who would otherwise need to discontinue them due to recurrent hyperkalemia.
How Lokelma works:
Hyperkalemia (elevated serum potassium) is a serious electrolyte disturbance commonly seen in chronic kidney disease, heart failure, and patients on renin-angiotensin-aldosterone-system blockers (ACE inhibitors, ARBs, MRAs, finerenone), potassium-sparing diuretics, NSAIDs, and other medications. Severe hyperkalemia causes life-threatening cardiac arrhythmias.
Lokelma’s zirconium silicate framework selectively exchanges hydrogen and sodium ions for potassium in the GI tract — trapping potassium for fecal excretion. Selectivity for potassium over other cations distinguishes it from older SPS. Onset is fast enough for acute management; chronic dosing enables potassium control while continuing RAAS blockade. Particularly valuable in CKD and HF where stopping ACE/ARB/MRA for hyperkalemia worsens cardiorenal outcomes.
Form and use:
Lokelma powder for oral suspension in single-dose packets (5 g and 10 g). Initial: 10 g three times daily for up to 48 hours for acute hyperkalemia. Maintenance: 10 g once daily; titrate based on serum potassium. Mix powder with water (3 tablespoons) and drink immediately. Do not swallow whole packet. Administer at least 2 hours before or 2 hours after other oral medications (binds many drugs in the gut).
Generic availability:
No generic Lokelma. Other potassium binders: patiromer (Veltassa — calcium-potassium exchanger, daily powder, similar mechanism, often comparable cost), sodium polystyrene sulfonate (Kayexalate generic — older binder, much cheaper but slower onset, GI side effects, rare colonic necrosis especially with sorbitol; can cause sodium overload), calcium polystyrene sulfonate (Kionex generic — alternative for sodium-restricted patients). Acute severe hyperkalemia treatment (cardiac membrane stabilization and intracellular potassium shifting): IV calcium gluconate or chloride, insulin (10 units) + IV glucose (D50W), inhaled beta-2 agonist (albuterol nebulizer), sodium bicarbonate (if acidemic), urgent dialysis for severe or refractory cases. Address underlying drivers: review medication list for RAAS blockers, MRAs, K-sparing diuretics, NSAIDs, trimethoprim, heparin, beta-blockers, digoxin; treat acute kidney injury; manage diabetes; restrict dietary potassium where appropriate; address constipation that reduces fecal K loss.
Warnings:
Edema (sodium absorption — caution in HF, hypertension, edema-prone states; consider lower dose), hypokalemia (over-treatment — monitor serum K), drug interactions (binds many oral drugs in the gut — separate by 2 hours, especially levothyroxine, antibiotics, anticoagulants, antidepressants, antiarrhythmics, immunosuppressants), gastrointestinal effects (nausea, constipation, vomiting — typically mild). Use during pregnancy: limited data, weigh risks vs benefits. Lactation: limited data. Avoid in conditions with severely impaired gut motility.
FAQ (Frequently Asked Questions)
How Much Does Lokelma Depot Cost Without Insurance?
Brand Lokelma $700–$1,000 per month. Patiromer (Veltassa — alternative newer binder) costs $800–$1,000 per month. Generic sodium polystyrene sulfonate (Kayexalate generic) costs $20–$50 per month but has more side effects and slower onset.
What is hyperkalemia and why does Lokelma help?
Hyperkalemia is dangerously elevated potassium in the blood — common in CKD, heart failure, and patients on ACE inhibitors, ARBs, MRAs, finerenone, K-sparing diuretics, and NSAIDs. Severe hyperkalemia causes life-threatening cardiac arrhythmias. Lokelma traps potassium in the gut for fecal excretion — lowering serum potassium and enabling continued use of guideline-directed therapies that would otherwise need to be stopped.
What is the difference between Lokelma and Veltassa (patiromer)?
Both are newer potassium binders that enable chronic potassium management with better tolerability than older Kayexalate. Lokelma is a zirconium silicate; Veltassa is a calcium polymer. Lokelma has faster onset (within 1 hour) and is taken at higher initial dosing for acute hyperkalemia. Veltassa is dosed once daily. Both bind many oral medications in the gut — separation required.
What is the difference between Lokelma and Kayexalate?
Both bind potassium in the gut. Kayexalate (sodium polystyrene sulfonate) is much older — slower onset, more GI side effects (constipation, nausea), rare but serious colonic necrosis especially when given with sorbitol, sodium overload concerns. Lokelma is better tolerated, faster acting, and safer for chronic use. Cost difference is substantial — Kayexalate is very cheap
Why is Lokelma valuable for patients with heart failure or CKD?
Patients with HF and CKD benefit substantially from RAAS blockade (ACE inhibitors, ARBs, MRAs, finerenone) and SGLT2 inhibitors — but these medications cause hyperkalemia in some patients. Without potassium binders, prescribers often have to reduce or stop these life-saving therapies. Lokelma and Veltassa enable continued GDMT (guideline-directed medical therapy) in patients with chronic hyperkalemia.
What are the major Lokelma drug interactions I should know about?
Lokelma binds many oral drugs in the gut — reducing their absorption. Separate other oral medications by at least 2 hours before or after Lokelma, especially levothyroxine, antibiotics (tetracyclines, fluoroquinolones), anticoagulants (warfarin, dabigatran), antidepressants, antiarrhythmics, immunosuppressants (tacrolimus, cyclosporine, mycophenolate), digoxin, and statins.
Can Lokelma cause swelling or worsen heart failure?
Possible — Lokelma releases sodium during the potassium-exchange process. Caution in heart failure, hypertension, and edema-prone states. Lower dose or alternative binder (Veltassa) may be preferred in these patients.
What happens if my Lokelma Patient Assistance Program application is denied?
We help explore patiromer (Veltassa — alternative newer binder, similar mechanism) copay programs, generic sodium polystyrene sulfonate (Kayexalate generic — much cheaper but more side effects and slower onset), Medicare Part D Extra Help, foundation aid (National Kidney Foundation, American Heart Association, Patient Access Network, NeedyMeds), nephrology and cardiology consultation for medication review and dietary potassium management, and consideration of dialysis for severe refractory hyperkalemia.
Take Control of Your Medication Costs
Chronic hyperkalemia management should not be skipped over cost — enabling continued RAAS blockade and SGLT2 inhibitor therapy is critical for heart and kidney outcomes. Our Lokelma advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Lokelma through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.